PharmaTrac

acquaint
Oct’24 dataset

Authored by:
Ms. Mona Kazi
Ms. Shalvi Kunde
 Table of Contents

01 02 03
Industry Acute/Chronic Supergroup
Scenario Split Gauger

04 05
New introduction Contact
Dynamics Information

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 2
 Industry Scenario
1.1 Therapy overview
In the month of Oct’24, the Indian Pharmaceutical Market (IPM) showcased impressive value
growth, reaching a market value of 19,610 Cr. This represents a 6.06% increase in value and
an incremental gain of 1122 Cr compared to the previous period. On a moving annual total
(MAT) basis, the market hit 2,18,502 Cr, reflecting an 7.7% year-over-year growth and a
compound annual growth rate (CAGR) of 10.4%, indicating robust and sustained expansion in
the sector.

Key therapeutic areas that have driven this growth are Cardiac, Gastrointestinal, Anti-diabetic,
Neuro/ CNS, Derma, Ophthal/ Otologicals, Urology, Stomatologicals and Sex Stimulants/
Rejuvenators and have showcased a notable growth performance in both sales value and
volumes. Additionally, segments such as Blood related, Gynaecological and Hormones have
experienced value growth rates relatively better than the overall market.

MTH SALES VALUE MTH VAL GR%

MAT VAL
SUPER GROUP OCT OCT OCT OCT OCT OCT 5 YR.
OCT 24
20 21 22 23 24 24 AVG
IPM 218502 13362 15379 15952 18488 19610 6% 10%
CARDIAC 29379 1700 1876 1994 2285 2549 12% 11%
ANTI-INFECTIVES 25682 1856 2272 2107 2494 2477 -1% 8%
GASTRO INTESTINAL 26119 1475 1787 1810 2109 2267 8% 12%
ANTI DIABETIC 19912 1299 1477 1414 1593 1742 9% 8%
VIT / MIN / NUTR 19518 1268 1376 1439 1680 1742 4% 8%
RESPIRATORY 16413 917 1245 1315 1577 1522 -3% 14%
PAIN / ANALGESICS 15179 871 1056 1130 1319 1372 4% 12%
NEURO / CNS 14600 827 961 1028 1188 1290 9% 12%
DERMA 13860 915 926 1014 1119 1243 11% 8%
BLOOD RELATED 6709 468 452 490 581 624 7% 8%
GYNAECOLOGICAL 7031 393 431 486 566 592 5% 11%
ANTI-NEOPLASTICS 4713 214 276 378 398 410 3% 18%
OPHTHAL / OTOLS 4110 218 270 303 332 364 10% 14%
UROLOGY 3498 214 214 232 278 328 18% 12%

Table 1: Top 95% contributing therapy performance

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 3
 1.2 Growth drivers
The overall growth of 6.1% for the month of Oct’24 is majorly contributed by Price and NI where
pricing continues to drive the market. The volumes have slowed down for the month amongst
majority of the therapies except Cardiac, Derma, Ophthal/ Otologicals, Urology, Hormones and
Sex Stimulants/ Rejuvenators.

Price hikes continue to play an important role in price growth of IPM contributed by all the
therapies. Among the 70% contributing therapies, the highest price hike of 6.5% is seen in
Gastro Intestinal therapy followed by Cardiac and Vit/ Min/ Nutr.

Anti-diabetic, Neuro/ CNS, Derma, Urology, Anti-neoplastics, Ophthal/ Otologicals, Hormones

and Stomatologicals have shown relatively higher new introductions led growth in comparison
to overall IPM NI growth. Blood related have continued to showcase the highest new
introduction growth of 5.8% majorly due to launches in Ferric Carboxymaltose category.

20 Vol GR Price GR NP GR

15 3.7

10 2.0 3.0 7.3

2.7 4.6 2.7 2.7 5.8 4.6
5.8 1.9 1.9
% Growth

5 5.9 2.0
0.8 6.8
6.3 5.3 5.8 5.6 5.2 6.0 4.5 3.8 3.8
3.7 3.8 4.2
2.3 1.0
0
-0.5 -3.1 -0.2 -2.9 1.1
-5.2 -1.5 -4.8 -1.6 -1.6
-5 -11.0

-10
11.5 -0.7 7.5 9.4 3.7 -3.5 4.0 8.6 11.1 7.4 4.5 3.1 9.5 17.8
-15

Figure 1: Top 95% contributing therapy month growth drivers

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 4
 1.3 Zonal Split

20
NORTH ZONE EAST ZONE 14
18

16 12

14
10
12

Value Gr%
10 8

Value Gr%
8
6
6

4 4

2
2
0
3,318 3,873 3,861 4,539 4,822 2,939 3,206 3,567 4,029 4,305
-2 0
Oct-20 Oct-21 Oct-22 Oct-23 Oct-24 Oct-20 Oct-21 Oct-22 Oct-23 Oct-24
MAT VAL VAL GR%
MAT VAL VAL GR%

28 16
WEST ZONE 26 SOUTH ZONE
24 14
22
20
12
18
16
10
14
12
Value Gr%

Value Gr%
10
8
6 6

4
2 4
0
-2 2

2,885 3,631 3,476 4,199 4,585 -4

3,579 3,958 4,315 4,912 4,983
-6 0
Oct-20 Oct-21 Oct-22 Oct-23 Oct-24 Oct-20 Oct-21 Oct-22 Oct-23 Oct-24
MAT VAL VAL GR% MAT VAL VAL GR%

Figure 2: Zonal monthly progression in IPM - same period - Oct - value wise - 5 trends

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 5
 The graphical plot above represents the zonal progression in terms of value in the month of
Oct’24 over the last 5 periods.

The zonal skew for the IPM in Oct'24 has continued to show a dispersion of S-N-W-E in terms
of value and N-S-W-E in units. On a value basis, almost equivalent spread ranging between
22% - 25% is exhibited by all the four zones.

Whilst all 4 zones have demonstrated positive value growth; West zone continued to exhibit
the highest value growth of 9.2%.

Regions like Delhi, Rajasthan, and Haryana have continued to outperform in the North zone.
Within the West zone, Gujarat, Mumbai MMR, Pune and South Maharashtra showcased
positive uptake in both value and volumes.

Karnataka and Tamil Nadu have demonstrated healthy value growth for the month amongst
South zone. Odisha in the East zone has shown promising growth for the month of Oct’24.

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 6
 Acute/Chronic Split
2.1 Monthly trend
In the month of Oct’24, positive value growth was seen across all the segments with chronic
segment showcasing positive volume growth.

A sales incremental of 1122 Cr has been added to the IPM over the month SPLY with chronic
therapy contributing 49% to the incremental value followed by sub chronic segment with 24%.

10000 25%

9000

8000 20%

7000
Sales value in Cr

% Val Growth
6000 15%

5000

4000 10%

3000

2000 5%

1000

0 0%
OCT 20 OCT 21 OCT 22 OCT 23 OCT 24
ACUTE CHRONIC SUB CHRONIC ACUTE CHRONIC SUB CHRONIC

SALES VAL (IN CRs) % VAL GROWTH

Figure 3: 5-year month-on-month trend for Acute/Chronic split

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 7
 2.2 Market dominance
2.2.1 Acute segment

Acute portfolio holding ~47% distribution over the last 5 years has contributed to 9160 Cr sales
in the IPM for month of Oct’24. A value growth of 2.6% has been registered by the acute
segment with an incremental value of 236 Cr.

Among the top 5 corporates, Sun* continues to lead the market while Alkem*, Abbott* and Cipla
have moved up to secure 2nd, 4th and 5th position majorly due to their pillar brands exhibiting
an encouraging traction for the month. Dr. Reddys has gained a rank from its immediate
competitor in the acute segment. Corporates namely, Torrent, Intas and FDC have
demonstrated an outstanding performance for the month in acute segment gaining ranks to
secure 14th, 16th and 19th position in the top 20 leaderboard.

Brands like Clavam, Pan D, Udiliv and Zerodol SP among the top 10 brands have shown a
relatively higher value growth than the segment for the month of Oct’24.

Within the next 30 players, La Renon, Cadila, Allergan, Corona, Reliance, Bayer, and Roche
have exhibited an incredible performance over the last year in acute therapy and have been
able to gain significant ranks. A remarkable performance has been portrayed by Samarth LS
with its robust value growth to climb up the ladder by nine ranks.

Table 2: Top 20 players performance in acute segment

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 8
 2.2.2 Chronic segment

Chronic segment, contributing to ~32% of the IPM value with 6243 Cr growing at 9.7% by value
and added an incremental value 553 Cr for the month.

Among the top 5 players, all the corporates have maintained their positions for the month.
Glenmark has gained one rank securing 10th position from its immediate competitor. Micro, and
Aristo have gained ranks to secure 13th, and 18th rank respectively.

Within the next 30 players, AstraZeneca, Merck, Bayer, Systopic, Unison, Akumentis and Med
Manor have exhibited an incredible performance over the last year in chronic therapy and have
been able to gain significant ranks. Similarly, corporates like GSK, La Renon, Lloyd HC, and
Janssen have gained one rank each.

Mixtard, Ryzodeg, Thyronorm and Rybelsus have shown commendable value growth for the
month amongst the top 10 brands in chronic category.

Table 3: Top 20 players performance in chronic segment

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 9
 2.2.3 Sub-chronic segment

The sub-chronic category contributing 21% by value to the IPM has recorded a sales value of
4026 Cr growing at value growth of 7%.

Sun* has secured the 1st position by gaining two ranks and a market share of 0.6% for the
month of Oct’24. GSK has gained ranks to move up to the 8th position leveraging its positive
value growth. Nutricia International Pvt. Ltd. and Pfizer, with commendable growths for the
month, have earned significant ranks.

Hegde & Hegde, Micro, Galderma, Akumentis, UNS, Wockhardt, Ajanta and Pure & Cure
healthcare have gained two or more ranks among the next 50 corporates leveraging their
double-digit value growth performance in the month of Oct’24. Additionally, KLM has exhibited
encouraging value and volume growth fostering its gain of seven ranks in the segment.

Table 4: Top 20 players performance in sub-chronic segment

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 10
 Supergroup Gauger
3.1 Corporate standings
Listed are the leading 5 corporates ranked on month Oct’24 in each of the therapies. Relative
indexing has been done based on the overall therapy vs corporate value growth for the month.
CORPORATE RANKING 1 to 5

SUPER GROUP TOP THERAPY LEADERS

CARDIAC SUN* TORRENT LUPIN USV MANKIND*

ANTI-INFECTIVES ALKEM* ARISTO MACLEODS CIPLA MANKIND*
GASTRO INTESTINAL ABBOTT* SUN* ALKEM* TORRENT ARISTO
ANTI DIABETIC ABBOTT* USV SUN* LUPIN ERIS LS
Nutricia Int. PROCTER AND
VIT / MIN / NUTR ALKEM* ABBOTT* MANKIND*
[Link] GAMBLE HEALTH
RESPIRATORY CIPLA LUPIN MANKIND* GLENMARK SUN*
PAIN / ANALGESICS IPCA SUN* ALKEM* GSK DR. REDDYS
NEURO / CNS SUN* INTAS TORRENT ABBOTT* CIPLA
HEGDE & DR.
DERMA GSK GLENMARK SUN*
HEGDE REDDYS
BLOOD RELATED EMCURE* ZYDUS* FRANCO INTAS ALKEM*
GYNAECOLOGICAL MANKIND* SUN* ABBOTT* ZYDUS* INTAS
ANTI-NEOPLASTICS INTAS ZYDUS* MANKIND* EMCURE* DR. REDDYS
OPHTHAL / OTOLS SUN* ALLERGAN AJANTA CIPLA NOVARTIS*
DR.
UROLOGY CIPLA SUN* INTAS INDOCO
REDDYS
HORMONES ABBOTT* MACLEODS GSK SUN* PFIZER*
DR. SERUM BIOLOGICAL
VACCINES GSK RELIANCE
REDDYS INSTITUTE E
DR. WIN-
STOMATOLOGICALS INDOCO ICPA GROUP
REDDYS MEDICARE
SEX STIMULANTS /
MANKIND* MACLEODS HIMALAYA CIPLA SUN*
REJUVENATORS
ANTI MALARIALS IPCA ZYDUS* THEMIS MACLEODS ARISTO

Table 5: Therapy wise top 5 corporate standings Color index: CORPORATE MTH GR % > THERAPY MTH GR
CORPORATE MTH GR % < THERAPY MTH GR

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 11
 New Introduction dynamics
4.1 Therapy wise new introductions
5032 New Introductions (SKUs) have a value contribution of 2709 Cr and this contributes 1.2%
to the IPM (MAT Oct’24). For the Month of Oct’24, NIs have contributed 2.4 % to IPM, with 391
new SKUs / Brands being launched in Oct’24. The past 2 months have seen below average
launches in terms of SKUs in the IPM.

The top 5 therapies with the highest number of new SKU launches (MAT Oct’24) are Derma,
Anti-diabetic, Gastrointestinal, Cardiac and Vit/ Min/ Nutr.

Although, maximum number of new launches are seen Cosmo-derma therapy in

Dermatologicals, OADs Combinations in Anti diabetic, and Anti-bacterials in Anti-infectives, the
per SKU value in these segments is below the IPM average of 0.54 Lac per year.

DERMA 216
478
ANTI DIABETIC 173
400
GASTRO INTESTINAL 334
368
CARDIAC 296
353
VIT / MIN / NUT 364
342
ANTI-INFECTIVES 125
316
PAIN / ANALGESICS 107
266
NEURO / CNS 151
255
RESPIRATORY 179
227
BLOOD RELATED 166
126

0 50 100 150 200 250 300 350 400 450 500

MAT_VAL_OCT_24 No of SKU

Figure 5: New Introductions in top therapies NI- Number of SKUs

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 12
 4.2 NI behavior – Subgroups
26 new subgroups – plains and combinations are launched in the last 12 months. Anti-diabetics
and Respiratory supergroup have seen the maximum number of newly launched subgroups.
The highest value contributing Supergroup is Gastro Intestinal, followed by Respiratory
therapy.

Unique triple drug combination of Fluticasone + Umeclidinium + Vilanterol; launched by GSK

as a patient friendly approach to counter the increasing cases of Chronic obstructive pulmonary
disorder has ticked the highest value in the category of new subgroup launches.
SUBGROUP MAT
No. of
LAUNCH SUPER GROUP SUBGROUP VAL
Brands
DATE OCT 24
Total 84 129.97
Oct-24 CARDIAC DAPAGLIFLOZIN + METOPROLOL 1 0.0
Aug-24 ANTI DIABETIC DAPAGLIFLOZIN + LINAGLIPTIN + METFORMIN 14 5.8
Jun-24 ANTI DIABETIC SITAGLIPTIN + GLIMEPIRIDE 2 0.5
Jun-24 DERMA SYNDET BASE SOAP 1 0.1
Jun-24 GASTRO INTESTINAL PLECANATIDE 2 1.6
Jun-24 NEURO / CNS DEXTROMETHORPHAN + BUPROPRION 6 4.2
CALCIUM + CHOLECALCIFEROL + L
Jun-24 VIT / MIN / NUTR METHYLFOLATE + METHYLCOBALAMIN + 1 0.1
PYRIDOXAL-5-PHOSPHATE
May-24 CARDIAC AZELNIDIPINE + METOPROLOL 1 0.2
May-24 DERMA ABROCITINIB 1 0.4
May-24 GASTRO INTESTINAL VONOPRAZAN 26 45.5
May-24 NEURO / CNS ETIFOXINE 1 3.0
Apr-24 ANTI-NEOPLASTICS SELUMETINIB 1 0.1
Mar-24 ANTI DIABETIC INSULIN GLARGINE + LIXISENATIDE 1 7.9
Mar-24 CARDIAC INCLISIRAN 2 2.9
Feb-24 NEURO / CNS LASMIDITAN 7 3.3
Feb-24 OPHTHAL / OTOLS HYDROCORTISONE + GLACIAL ACETIC ACID 1 0.1
Feb-24 RESPIRATORY FLUTICASONE + UMECLIDINIUM + VILANTEROL 1 17.5
Feb-24 RESPIRATORY FEXOFENADINE + PSEUDOEPHEDRINE 1 0.3
Jan-24 ANTI DIABETIC DAPAGLIFLOZIN + GLICLAZIDE 1 0.9
Jan-24 ANTI DIABETIC SITAGLIPTIN + GLICLAZIDE 1 1.2
Jan-24 ANTI-NEOPLASTICS RELUGOLIX 3 3.7
Jan-24 RESPIRATORY GLYCOPYRROLATE + VILANTEROL 2 0.7
BILASTINE + DEXTROMETHORPHAN +
Jan-24 RESPIRATORY 2 2.3
PHENYLEPHRINE
Nov-23 DERMA NIACINAMIDE + VITAMIN E 1 0.4
Nov-23 RESPIRATORY FLUTICASONE + GLYCOPYRROLATE + VILANTEROL 3 7.6
*Sorting on Subgroup Launch date (Newest to oldest)

Table 6: Last 12 months new molecular launches

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 13
 4.3 Blockbuster new introductions
NI brand’s contribution remains constant at 1% contribution to the total sales turnover of the
IPM for the month of Oct’24.

Launched in different therapies, 25 brands listed below have managed to tick off a remarkable
benchmark of more than one crore for the month and their contribution remains constant at
27% of the monthly NI value.

BRAND LAUNCH SALES VAL OCT

BRAND CORPORATE SUBGROUP
DATE 24

MONTH NI VALUE 185.44

Feb-24 CIDNAVIR EMCURE* CIDOFOVIR 8.36
Jul-24 PROHANCE LIV SUN* PROTEIN SUPPLEMENTS 3.61
Dec-23 VORXAR TORRENT SAROGLITAZAR 3.6
TRELEGY FLUTICASONE +
Feb-24 GSK 2.65
ELLIPTA UMECLIDINIUM + VILANTEROL
Oct-24 ALBUCEL XP INTAS HUMAN ALBUMIN 2.54
Jan-24 LYVELSA SUN* FINERENONE 2.23
Aug-24 STARIZO SUN* TEDIZOLID 2.14
Dec-23 LINVAS (LUPIN) LUPIN SAROGLITAZAR 1.96
SOLIQUA INSULIN GLARGINE +
Mar-24 SANOFI INDIA 1.77
SOLOSTAR LIXISENATIDE
CALCIUM +
CHOLECALCIFEROL + FOLIC
Nov-23 CORCIUM XT LUPIN 1.77
ACID + METHYLCOBALAMIN +
PYRIDOXINE
Nov-23 INSUQUICK USV REGULAR ASPART 1.66
Jun-24 KABVIE TORRENT VONOPRAZAN 1.63
Jan-24 UNS D3 UNS CHOLECALCIFEROL 1.63
CALCIUM CARBONATE +
Dec-23 RANIDOM RAFT MANKIND* SODIUM ALGINATE + SODIUM 1.57
BICARBONATE
Jun-24 VONOMAC MACLEODS VONOPRAZAN 1.48
Jun-24 VERSAVO PLUS DR. REDDYS BEVACIZUMAB 1.41
ASTHAKIND
Jan-24 MANKIND* LEVOCLOPERASTINE 1.4
PRO
Mar-24 GANTRA DR. REDDYS VERICIGUAT 1.39
GUFIC
Jun-24 ZARCEPTA CEFTAZIDIME + AVIBACTAM 1.22
BIOSCIENCE
Mar-24 ISOFIT SR ALEMBIC DYDROGESTERONE 1.13
Jun-24 VONO (DRL) DR. REDDYS VONOPRAZAN 1.11

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 14
 Jun-24 PETRIL MD MICRO CLONAZEPAM 1.09
FERRIC CARBOXYMALTOSE
Nov-23 HEMFER FCM ALKEM* 1.05
COMPLEX
OVIGYN D DEHYDROEPIANDROSTERONE
Aug-24 ALEMBIC 1.04
PLUS COMBINATIONS

Table 7: Last 12 months new brand launches

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 15
 About the Author
Mona Kazi, Associate Vice President Commercial, Pharmarack
Mona possesses over 23 years of expertise within the pharmaceutical industry, spanning
sales, marketing, data analytics, and business insights. Armed with a pharmaceutical life
science degree and a degree in marketing, she merges technical expertise with strategic
insight to drive impactful decision-making.

Contact: monak@[Link] ; 9867792373

Shalvi Kunde, Manager Commercial, Pharmarack

Shalvi has completed her dual degree of Masters in Pharmacy & MBA from one of the leading
institutes. She is a part of Pharmarack Commercial Team with focus on Client Engagement
and Market Insights.

Contact: shalvik@[Link] ; 8805302593

Your Feedback Matters!

At Pharmarack, we value your input and feedback. We believe that collaboration with our esteemed
readers and industry experts is crucial for the success of this initiative. We invite you to share your
thoughts, comments, and queries if any to monak@[Link] / shalvik@[Link] . Your
feedback will help us tailor “Acquaint” to better meet your needs and expectations.

Source: PHARMATRAC MAT OCT 2024 VAL IN CR ; UNITS IN 000 | The Content of this Industry Report is property of Pharmarack. Any replication/publication without authorization
would amount to legal action 16